Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. uri icon

Overview

abstract

  • A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin (mTOR) inhibitor everolimus, initially randomized to placebo (but had disease progression after 3 months) and crossed over to everolimus at time of unblinding. The patient had stable disease after 8 weeks (two cycles) of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication (after TKI therapy with sunitinib or sorafenib).

publication date

  • August 10, 2010

Research

keywords

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Lung Neoplasms
  • Salvage Therapy
  • Sirolimus

Identity

PubMed Central ID

  • PMC3219862

Scopus Document Identifier

  • 84655176768

Digital Object Identifier (DOI)

  • 10.1007/s12032-010-9640-y

PubMed ID

  • 20697842

Additional Document Info

volume

  • 28

issue

  • 4